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1. Introduction 
Tuberculosis (TB) remains the leading cause of death
from a curable infectious disease
1, despite the
availability of short-course therapy that can be both
inexpensive and effective.
Clinical management of cases in developing countries
is hampered by the lack of a simple and effective
diagnostic test. Correct diagnosis of TB is needed to
improve treatment, reduce transmission, and control
development of drug resistance.
In patients with active pulmonary TB, only an
estimated 45% of infections are detected by sputum
microscopy
2. This test, first developed in the 1880s and
basically unchanged today, has the advantage of being
simple, but is hampered by very low sensitivity: it may
only detect half of all cases with active infection. It is
also very dependent on the skill of the technician, and
a single technician can only process a relatively small
number of slides per day
3. Furthermore, a staggering
three million people who present annually with
suspected TB may not be properly diagnosed, because
their infection (so-called smear-negative disease)
cannot be detected by sputum microscopy
4.
There are specific epidemiological factors that present
additional challenges to TB diagnosis. HIV infection is
thought to be a major contributor to the increase in TB
incidence across the world
2. An estimated 9% of adults
globally with newly diagnosed TB are HIV positive, but
this rate is 31% in Africa
5. HIV co-infection with TB
presents challenges to effective diagnosis of TB and
diagnosis can also be more difficult in children.
The rapid rise of drug-resistant (DR) TB has further
complicated TB diagnosis
6. Tests that measure drug
susceptibility are essential to monitor the spread of
resistant TB strains, and ensure that patients are given
effective treatment. The recent cluster of so-called
extensively drug resistant (XDR) TB cases in South
Africa were untreatable by any available drugs, and had
a devastating mortality rate: 52 of 53 patients died
7.
New diagnostic tests that are simple and robust
enough to be used in the field, accurate enough to
diagnose all infected individuals, and able to identify
drug resistance are desperately needed, and represent
an essential complement to new drug development
efforts and to effective control and treatment
programmes.
Reviewing the TB diagnostics
development landscape
In 2005, Médecins Sans Frontières (MSF) treated
17,000 patients for tuberculosis in 94 programmes
across 44 countries. This analysis of the TB diagnostics
research and development (R&D) pipeline, along with
an accompanying report on the TB drug development
pipeline
8, stem from the frustration of MSF medical
practitioners at the lack of simple, reliable tools for
detecting TB at point-of-care, and by the growing need
for drug susceptibility testing in MSF and other
programmes.
This report aims to review the current status of the
development of new diagnostics for TB, and to
answer the questions: What can we expect from the TB
diagnostics pipeline? and What do we need to do to
ensure that effective tools are developed?
The report draws upon a review of the literature,
company listings, direct contact with scientists,
researchers and companies, and input from MSF
doctors and laboratory technicians working in MSF
projects around the world. MSF doctors treat TB
patients in specialised TB projects, in HIV/TB integrated
programmes, in primary health care contexts, and in
specialised drug resistant TB settings. This report
draws on their experience and frustrations and tries to
determine whether the tools that are being developed
are likely to respond to the needs identified.
The diagnostic pipeline
This report presents the diagnostics pipeline divided
into tests that require culture and those that do
not. We have used this division because setting up
culture facilities requires a particular investment of
resources and expertise, and MSF field experience has
shown that this is often more complicated and difficult
to realise in the field than is widely appreciated. 
However, culture remains the gold standard, and is
often the most sensitive test for TB. Drug sensitivity
testing is dealt with in both sections. We distinguish
between tests that are already available and those
under development, and describe the stage of
development and the potential interest for field
application, where possible.
The criteria for field application are based mainly on5
feedback from MSF projects, which is both a limit and
a strength in such an analysis. We do not claim that
tests that are not adapted to MSF settings are
therefore not interesting. We limit ourselves to sharing
our experience and the result of our ongoing efforts to
improve our medical practice.
For any diagnostic test to be useful, it must deliver
information that is used to make a medical decision. It
is crucial for the TB diagnostic pathway to be viewed
in this context – will a given test, when used in the
setting in which it is applied, give a result that is
interpretable and that will allow a medical decision to
be made? Do the resources exist to apply and interpret
the test, and can the doctor or health care worker
propose something to the patient based on the
information obtained?
In some cases it has been hard to find evidence that
these aspects have been considered in the design of
the test.
Many of the projects to develop TB diagnostics are
funded by The Foundation for Innovative New
Diagnostics (FIND), supported by the Bill & Melinda
Gates Foundation, which has committed US$30 million
over five years. This is an important contribution to
encouraging the development of new tests. However, it
is important that other projects and groups continue to
be active in the search for better tools, especially
because certain types of project, such as fundamental
research, are not part of the FIND strategy.
A major difficulty in preparing the report has been an
overall lack of transparency and limited availability and
sharing of information. This report is therefore certainly
incomplete. We would welcome comments and
clarification, and hope that this work will be a starting
point for a more open exchange of ideas and
strategies to deal with this very complex and
challenging public health crisis.
We stress the need for collaboration as the most
effective way forward.
The peripheral laboratory setting
In this report, we often talk about use of a test in a peripheral laboratory.
For MSF, this is:
• The most remote point of care at which suspected TB cases are diagnosed and treated.
• Basic laboratory facilities only: usually single room, often lacking electricity and water, understaffed, 
performing only sputum smear microscopy.
• Level of staff training and quality control can vary widely.
• No facilities for any culture tests (except very few urban facilities which may have rudimentary facilities for 
culture, and limited training).
• Frequently ill-equipped to handle high workloads.
• May lack any laboratory staff -- just used for sputum collection with testing done at central laboratory
However, the same conditions described above for a peripheral laboratory may be encountered in poorly
supported district hospitals or in urban areas. In this report, this term refers to the conditions that exist in the
settings where most of our patients are seen.6
Culture of Mycobacterium tuberculosis remains the
gold standard for both diagnosis and drug sensitivity
testing. This section reviews culture tests currently in
use, and newly developed techniques.
Culture-based tests are difficult to implement in the
field. They require dedicated facilities and staff, with
specific requirements for training, quality assurance,
biosafety, and equipment, which can take time and
significant local resources to set up. For culture to be
reliably implemented, local capacity needs to be
supported and developed.
Conventional culture methods using Lowenstein-Jensen
(LJ) or 7H11 medium, while cheap and simple, have
the major disadvantage of being very slow. LJ cultures
take 20 – 56 days for diagnosis and four to six weeks
after initial culture for drug sensitivity testing. 7H11
medium slightly accelerates the process, but requires
antibiotics in the medium to prevent contamination
and a CO2 incubator. Diagnosis with 7H11 medium
takes 17 –21 days, DST information is available three
to six weeks later.
Some more rapid culture methods have been
developed and are commercially available (Section
2.1), most of which are difficult to implement in the
field due to the complexity of the technique or the
required equipment. There are also some emerging
simplified culture techniques that can reduce time to
diagnosis or DST that seem more appropriate for use
in resource-limited settings (Section 2.2).
The sensitivity of culture is limited by the need to
have bacilli present in the sample to be cultured. HIV
positive patients and children have difficulty in
producing sputum and sputum culture will not detect
extrapulmonary (EP) forms of TB. EP TB is very
common in HIV positive patients and is rapidly fatal.
Even in patients with active pulmonary TB, the bacilli
may be protected in lung cavities or not present in a
particular sputum sample, or may be lost in the
decontamination treatment required to process
sputum for mycobacterial culture. All these factors limit
the usefulness of the technique.
2.1 New rapid commercial methods 
for diagnosis and DST
A number of commercial systems are available for
culture and DST, some of which may have slight
advantages in certain settings. However, none of the
tests are easily adaptable to the realities of field
projects, given the difficulties in setting up and running
culture laboratories.
2. Culture-based Methods7
Becton Dickinson (US).
No.
This system detects the presence of mycobacteria based on their metabolism rather
than visible colonial growth. A radioactive marker is present in the tube that is
detected by the machine when growth occurs.
No longer commercialised, but still available in some laboratories.
Faster than solid media.
Costs: the machine is expensive, and tests for DST cost Euro 13 for two drugs
tested per sample. These combine to make the technology more expensive than
the conventional culture method.
The machine requires appropriate laboratory infrastructure, including nuclear waste
disposal. In addition, the need for radioisotopes, needles, and the cost of
equipment limits its use to reference laboratories.
None. This technique is being phased out because of the difficulty associated with
using radioactive reagents.
Becton Dickinson (US).
FIND is involved with Becton Dickinson in a demonstration study for automated
MGIT aimed at assessing the cost and feasibility of the implementation phase of
BD Bactec system in developing countries.
Diagnosis through culture of samples (pulmonary and others). The MGIT system is
based on a glass tube, recently replaced by a plastic tube, containing 7H9 broth
together with a fluorescence quenching-based oxygen sensor. When inoculated with
M.Tb, consumption of oxygen produces fluorescence when illuminated by a UV
lamp.
The fully automated version can incubate up to 960 samples for M.Tb diagnosis
through culture of samples (pulmonary and others), and drug sensitivity testing for
first-line drugs.
Commercialised.
High throughput capacity
Automated, standardized reading of samples
Speed: diagnosis 7 days for sputum positive, up to 42 days for a negative result
DST 8 to 12 days (starting from culture)
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Rapid liquid TB culture medium: BACTEC MGIT 960® (automated)
BACTEC 460-TB®8
Machine is extremely expensive, priced at Euro 40,000 in Europe, up to 
Euro 100,000 in Africa.
Requires specific training of technical personnel. Liquid media are technically limited
as they are prone to contamination.
The machine must be maintained, this requires very frequent technical support from
the company.
Very limited due to the price and the dependence of the machine on service. The
advantage of this technique is the increased speed of diagnosis. However, 7 days
by MGIT corresponds to a sample that would have been positive by smear
microscopy, which gives a result in hours. This shows the need for a very thorough
analysis of what a test is used for and where before adopting a given technology.
This method gives comparable results to the BACTEC 460-TB® radiometric system
described above.
Becton Dickinson (US).
Yes.
See above for the automated system principle.
In the manual system, detection is performed by the technician visually using a
hand-held UV lamp.
Field evaluated by MSF.
The MGIT machine is not required.
More samples can be processed than conventional culture, although fewer than the
automated system.
Speed: diagnosis 7 days for sputum positive, up to 42 days for a negative result
DST 8 to 12 days (starting from culture).
Tubes are very expensive (Euro 4) “Developing country” price has been negotiated
by FIND (no information available).
Manual MGIT also requires additional reagents, manipulations and use of a
handheld UV lamp.
Liquid media are known to have a high percentage of contaminations leading to
unreliable results.
MGIT can only be used in a culture facility, which limits its implementation.
However, the handheld reader makes the technique machine independent and
cheaper and appears to give acceptable results when implemented in a laboratory
that already has experience with culture.
Disadvantages
Interest in peripheral
laboratory settings?
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Rapid liquid TB culture medium: MGIT (manual)9
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Organon Teknika (Netherlands).
No.
This technique for diagnosis and DST for first- and second-line drugs is an
automated non-radiometric continuous monitoring system with computerized
database management.
The system is based on detection of CO2 as an indicator of bacterial growth in
cultures in a closed and a fully automated system
9,10.
Commercialised.
This system can be used for first- and second-line detection of drug resistance
11,12.
System modular (machine and tubes can be bought separately), increasing
flexibility of use.
Relatively slow: diagnosis 17 days (range 7-40), DST 8 to 12 days.
Requires an expensive and non-robust machine, complicated and cumbersome.
Complicated and fragile, it is unlikely to be implemented in peripheral
settings.
AccuMed International (USA).
No.
This technique for diagnosis and DST for first-line drugs is a fully automated, non-
radioactive system, providing continuous monitoring of growth of mycobacteria
based on the detection of gases released by the bacteria
13.
Commercialised.
Cumbersome, not widely used.
Relatively slow: diagnosis 14 days (range 14-30), DST 15 days.
A method for testing susceptibilities of isolates of TB to first-line drugs has been
developed
14. However, the machine does not seem to provide advantages while still
being very slow.
Versa Trek system (previously called ESP culture system II)
MB/Bact T® system10
AB Biodisk (Sweden).
No.
The technique is based on determination of drug sensitivity testing using strips
containing gradients of impregnated antibiotics. The E Test strip is placed on the
surface of the solid culture medium and MICs (minimal inhibitory concentrations, a
measure of the susceptibility of a strain to an antibiotic) are determined by
interpreting the point at which the ellipse of inhibition crosses the strip.
Commercially available.
Simplicity, minimal training required.
Shown to be accurate and reproducible
15.
Relatively fast (five to ten days after primary culture).
Requires high bacterial concentration for inoculum i.e. needs to start from a culture.
Simple approach that does not require particular training of technical personnel.
Requires an initial culture step, which significantly limits its advantages.
Biotest (Germany).
No.
This system is based on the reduction of a tetrazolium salt indicator in liquid
medium
16. MB Redox® allows an easy macroscopic visualisation of the bacterial
growth. The tetrazolium salt indicator forms red to violet particles when reduced by
the growth of the mycobacteria.
Commercially available.
Simplified 96 well plate format, does not require specialised machine (can be read
by eye or simple spectrophotometer).
Cannot be used to measure DST on initially positive samples as dye is toxic;
visualisation is not easy; very few reports available; relatively slow (16 days for a
smear positive sample, 3 weeks for a negative result).
Interest would seem to be limited as better-performing alternatives exist.
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
MB redox®
E Test11
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Salubris (Turkey).
Yes (since July 2004).
The test uses a newly developed culture medium that changes colour depending on
the bacteria growing on it. The medium is initially red; if TB is present it turns
yellow. If it becomes green, the sample is contaminated with non-TB bacteria. The
colour changes are visible earlier than with the usual solid medium (Lowenstein
Jensen), and so reduce the time to an answer by about half (from roughly 6 weeks
to about 3 weeks).
The medium is under evaluation, but no details are available. No pricing information
available.
Ease of use and rapid results. The test is suitable for co-infected patients and
children as any kind of sample can be cultured. Another advantage is that there is
no need to open the tube to obtain a result.
Full TB culture facilities are required.
When the test becomes available it will likely allow simpler identification of TB
infection (by colour change) in a shorter time. We do not have any information
about how successful the development is and when a product might be available.
In addition to the commercialised systems above, the following test is being developed by FIND
Solid culture indicator medium: TK medium12
contamination, and even seemingly simple
requirements, like a stable power supply and a
functioning biosafety hood, are very difficult and
often enormously expensive to ensure. 
Metanalyses comparing phage based tests to culture
in field settings have shown that in most cases they
are no more informative that smear microscopy (see
box below).
2.1.1 Phage-based tests
Phage-based tests require limited culture facilities
and promise rapid results (~2 days). However,
MSF field evaluations shown that it is very hard to
implement in non-culture facilities in the field,
even in relatively well-supported urban settings. 
Dedicated areas are required, careful control of
access to the rooms is needed to reduce
Companies
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Biotec (UK and South Africa) for FASTPlaque TB test and FastPlaqueTB-RIF
TM, as well
as in-house systems.
Yes, for Biotec (since May 2004).
Diagnostic (FASTPlaque TB test) and rifampicin DST (FastPlaque TB-RIF
TM).
Phage tests are based on the ability of viable M. Tuberculosis to support the
replication of an infecting mycobacteriophage (a virus that infects mycobacteria).
Plaques of lysed cells in a lawn culture of mycobacteria are counted
17.
An evaluation study of the Rif phage test version is being conducted in Peru by
FIND. FASTPlaque is also being evaluated in Kenya in an MSF project. Preliminary
results show that the feasibility of technique is not optimal for a peripheral
laboratory. Final results will be available shortly.
Speed (2-3 days).
For in-house systems: relatively cheap.
Phage-based tests are technically complex to perform, requiring a well-functioning
bacteriology laboratory, a strict incubation protocol and well-trained technicians.
They are very labour intensive and some studies also report a high rate of
contamination, making the test and its results both difficult to perform and to
interpret.
FASTPlaque cannot be used for children or HIV-positive patients as it needs sputum.
Three days for a negative result is very interesting. However, this is only helpful if
the test is reliable and technically feasible. The consensus of a number of published
studies is that, given all these constraints, phage methods are less reliable than
smear microscopy, even if smears are poorly done. Given the enormous relative cost
and complexity of phage methods, they are looking less useful than originally
hoped
18.
Phage-based tests13
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Sequella Inc. (USA).
No.
The technique is used for DST.
This recombinant phage (phage which incorporated the gene for luciferase) can
express the luciferase gene when infecting a mycobacterium. In the presence of
luciferin substrate, infected bacteria emit light that can be detected with a
luminometer or by photosensitive film in a Polaroid film box called the “Bronx
Box”.
Under development, not commercially available.
Rapid result (2 days post culture).
To date, only limited reports of clinical application are available. The Bronx box is
not easy to manipulate. Conditions of use not clearly defined; needs repeated
testing.
Results obtained 40 hours post-culture.
Very limited due to technical constraints in using the system; requires an initial
culture step, which further limits its usefulness.
Luciferase reporter phages14
2.2 New rapid noncommercial methods for diagnosis and DST
There are also some tests that have not been commercialised that are of potential interest.
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Not commercialised, freely useable technique.
No.
This method is performed in liquid medium (7H9) with or without drug incorporated
in the medium
19,20.
A number of field evaluations have been published.
Quicker than solid culture, may be quicker than MGIT as volumes are smaller.
Fairly cheap, non-commercial, adaptable technique.
MODS is a delicate method that requires very experienced personnel.
As the test is performed in liquid medium, and needs to be handled often, it is
more of a biosafety risk for laboratory staff. The test requires an inverted
microscope, which is very seldom available or useful in field labs.
Some reports claim very good results
21, but when evaluated by two independent
experts for implementation in MSF field projects, both agreed that it is not easy to
use and requires a well trained and experience technician, which limits the settings
in which it could be introduced.
Not commercialised, freely useable technique.
No.
Used for DST of first-line drugs, the test is based on the ability of M. Tuberculosis to
reduce nitrate to nitrite by using the nitrate reductase enzyme
22,23.
Can be used from culture, needs to be validated for sputum or other clinical
samples.
Performed on solid media.
Only minimal training and no special equipment are required.
Relatively rapid results (10 days).
Readout of results is visual, not necessary to open the tubes therefore safer.
Nitrate reductase assay
MODS15
Only for DST for first-line drugs.
Low throughput.
Easy to implement in resource-limited settings. Further validation needed for use
from patient samples.
Not commercialised, freely useable technique.
No.
For diagnosis of M. Tuberculosis, plates with a thin layer of 7H11 agar medium are
incubated and examined microscopically on alternate days for the first two weeks
and less frequently thereafter. Microcolonies of M. Tuberculosis can be detected in
less than 7 days
24,25.
The technique has only recently been developed for DST as well (results not
published), but looks promising.
Validated for diagnosis. Under evaluation for DST use. More validation needed.
Test can be done with a standard light microscope.
It uses solid media, which is safer than liquid media.
No specific equipment is required.
The results are obtained in half the time of conventional culture. 
Diagnosis 5-10 days; DST 10-15 days.
Simpler to manage large numbers of samples than for manual liquid culture.
Requires a CO2 incubator (but could possibly be done in a candle jar, a simplified,
non-machine dependent equivalent)
Not as fast as liquid culture.
Cheap, requires no specific equipment, uses solid media. May give an acceptable
time to result. An interesting track to pursue as it may be a good compromise
between pragmatic constraints and the need for rapid results.
Disadvantages
Interest in peripheral
laboratory settings?
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Thin Layer Agar (microcolony detection)16
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Not commercialised, freely useable technique.
No.
Colorimetric methods for DST of first- and second-line drugs; based on the ability of
live bacteria to reduce a coloured indicator upon growth producing a change of
colour. M. Tuberculosis exposed in vitro to different antibiotics will reduce the
indicator only if it is resistant to these drugs
26,27. The test is also known as the
resazurin assay.
Validated in large field studies.
The test is performed in a small volume of liquid media.
It is easy to implement in resource-limited settings that have culture facilities (already
implemented in Latin America, Madagascar, Benin and Rwanda).
Only minimal training, and no special equipment required.
Rapid results in 8-10 days (especially for DST).
The test is done in 96-well dish, and is field-adapted.
Results determined visually by a colour change of the medium.
Only for DST (requires prior identification of M.Tb from culture) Euro 1.7 for two
drugs per sample.
Not as robust as thin layer, but has been shown to be feasible and practical in
laboratories with some culture capacity.
The exact cutoffs for determining DST levels need to be defined by the international
community before this can be included in a medical decision.
“Resa” Colorimetric method17
3. Non-Culture Methods
A number of strategies to detect and report the
presence of M. Tuberculosis have been developed.
Serology (detection of antibodies) has not produced
any reliable, informative tests despite decades of
work (Sect 3.1). Detection of antigens is a more
promising approach (Sect 3.2), as it detects the
presence of the organism and thus may be able to
diagnose active infection.
The use of nucleic acid amplification (NAA) tests
(Sect 3.3) in non-specialised laboratories is
technically challenging. These tests have been
shown to be highly specific, but sensitivity, if
starting from patient samples, is low and highly
variable, and is difficult to assess
28. These tests can
also be used from primary culture. Although this
improves the sensitivity, the technique is then very
slow. For this reason, we have decided to include
NAA tests in the non-culture section of this report,
in order to focus on the tests’ use on direct clinical
samples. Here we also look at some PCR based
techniques are being validated for use on patient
samples for rapid detection of rifampicin/isoniazid
resistance. There are also some tests being
developed that detect immunological responses
(interferon gamma assays). These tests are rather
expensive and complicated to perform, and still
need to be validated in endemic areas, and their
interpretation is not clear. We discuss these tests
and some projects that are at early stages of
research in Sect. 3.4.
3.1 Techniques using antibody 
detection
In 2005, WHO/TDR performed an evaluation of
commercially available rapid diagnostic tests (RDTs).
Twenty-seven manufacturers were invited to submit
their products for evaluation, but of the 19 who
agreed (Table 1), only six provided information on
the antigen used. All tests detect antibodies in
serum. Test samples came from the TDR specimen
bank.
Table 1. Manufacturers and tests reviewed in WHO/TDR study of RDTs.
1.  ABP Diagnostics Focus Sure Check TB
2.  Advanced Diagnostics Tuberculosis Rapid Test
3.  American Bionostica Rapid Test for TB
4.  Ameritek dBest One Step TB Test
5.  BioMedical Products Corp TB Rapid Screen Test
6.  Chembio TB Stat-Pak II
7.  CTK Biotech TB Antibody onsite Rapid Screening Test Kit
8.  Hema Diagnostic Rapid 1-2-3 TB Test
9.  Millenium Biotechnology Immuno-Sure TB Plus
10. Minerva  Biotech  V  Scan
11. Mossman  Associates  MycoDot
12.  Pacific Biotech Bioline TB
13.  Premier Medical Corporation First Response Rapid TB
14.  Princeton BioMeditech BioSign M.tuberculosis
15. Silanes  TB-Instantest
16.  Span Diagnostics TB Spot ver. 2.0
17.  Standard Diagnostics SD Rapid TB
18.  UniMED International Inc. FirstSign MTB Card Test
19.  Veda Lab TB Rapid Test18
The WHO study found that TB rapid diagnostic tests
currently available on the market vary widely in
performance, with some products showing a high
lot-to-lot and reader-to-reader variability. At less than
80%, the specificity was poor in the majority of
products when tested in TB suspected cases from
endemic settings. Those tests with a better
specificity (over 90%) had poor sensitivity, detecting
fewer than 40% of TB patients. The tests performed
even worse in HIV co-infected samples. The
conclusion of the study was that none of the assays
perform well enough even to replace microscopy
29.
Based on this and other information, it seems that
antibody detection is unlikely to be a good strategy
for the development of a reliable diagnostic test for
TB. It is important to note that the tests named in
the above table are only those that agreed to
participate in the study: absence from the list does
not imply that the test works. We found no
convincing evidence supporting the use of any
existing antibody detection tests.
3.2 Techniques using antigen 
detection
Several tests using antigen detection are currently
commercialised or under development.
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Chemogen (USA).
Yes (since April 2005). A “letter of intent” has been signed, according to FIND
information.
The test detects lipoarabinomannan (LAM) in urine as a surrogate marker for TB
infection. LAM is a component of the TB bacterial cell wall.
The test exists in Elisa and simplified ‘tube’ format. Clinical trials to develop a
dipstick format are ongoing. The simplified tube formatis apparently robust and
does not need cold chain.
The use of the test needs to be evaluated within a careful choice of algorithms, in
order to determine whether it will help guide clinical decision making. The tube
format requires at least three hours, several manipulations, a supply of distilled
water and some amount of training. It also requires reading the result in a
machine, but apparently a portable format has been developed. However, a
dipstick format would be very welcome.
The results of a preliminary study conducted in July 2003 in Tanzania on 242
suspect TB patients and 220 US healthy persons have been published
30.
In a separate project, the Swedish Institute for Infectious Disease Control is also
working with industrial partners to develop a urine dipstick detecting LAM.
The test may be suitable for children, co-infected patients, and extra-pulmonary
patients. A dipstick would be extremely useful as a high-throughput point-of-care
test. It holds potential for monitoring of treatment as LAM is in theory quickly
eliminated.
A urine sample is a good non-invasive approach. Possibly, there will be no need to
treat the urine sample prior to testing. This is currently a limiting step in many
field tests.
LAM urine test19
Disadvantages
Interest in peripheral
laboratory settings?
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
In its current form as an Elisa test, it is not suitable for the peripheral laboratory
setting, as it will require skilled staff, electricity supply, cold chain and specific
equipment. The tube format does not seem to completely address these problems,
but a dipstick, if it were to become available, will be a significant improvement.
Chemogen recommends boiling and centrifuging the urine, which is technically
difficult in many peripheral settings.
A urine dipstick that performs well and that eliminates the problems associated with
an Elisa test will be very useful in many peripheral and pointof-care situations. More
data and further evaluations are needed.
Proteome Systems (Australia).
Yes (since June 2005)-joint project on “reagent discovery science”
Note: the only information we have is from the company’s website.
Proteome Systems are using high throughput protein assays to identify antigens that
are specific to M. Tuberculosis and that could potentially be used to develop a rapid
test and diagnose active TB and infection, or to monitor treatment efficacy. They will
examine all types of biological fluids such as sputum, saliva, plasma or whole blood.
From what we know, the development is still at the research stage. According to an
initial press release, a rapid test was expected to be finalized by the end of 2005.
Proteome owns patents on four in vivo expressed TB proteins, method of preparing
sputum for 2 D gel analysis and an improved diagnostic testing apparatus for
multiple sample testing. How this will be translated into a test adapted for the
peripheral level is not clear.
Potentially interesting because antigen detection avoids some of the problems
associated with antibody detection. But there is no information about the preliminary
results on characterized samples, nor on the technical background nor on
performances of their format.
We also do not have information about the initial specifications of the test: did the
company look for molecules present in endemic populations or naïve groups, latent
versus active disease, pulmonary or extra-pulmonary, etc. This will affect the range of
possible uses for the test, and is important information in determining whether the
needs are being sufficiently addressed.
Information on the test is currently severely lacking. It appears there may be a need
for a reader or some kind of machine to perform the test.
Insufficient information available.
Antigen-based detection test20
Companies ANDA (France) for patho-tb and BioMed (India) for diagnos-tb.
ANDA to be evaluated with FIND.
Both tests rely on detection of M. Tuberculosis in sputum or body fluids with a
polyclonal antibody, using a flow-through device.
The ANDA test is currently under field evaluation. No information on laboratory or
field evaluation is available about the BioMed test.
Assessment of both tests in reference laboratory contexts, followed by further field
evaluation, would be useful.
BioMed’s diagnos-tb does not require boiling or centrifuging and seems to be easy
to perform.
The tests may increase the throughput of laboratories that have too many samples
to perform microscopy well. It may also increase sensitivity over microscopy.
For ANDA’s patho-tb, sample preparation requires decontamination and boiling, and
several manipulations including centrifugation.
For BioMed, insufficient information is available concerning the performance of the
test, although the company claims it is sensitive to 3000 bacteria/ml.
Sample preparation requirements mean that ANDA’s test could not be implemented
in very peripheral settings.
However, in high throughput laboratories or where microscopy is unreliable, it may
increase the detection rate or reduce the workload for microscopy.
Companies
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Flow-through filter tests21
NAA techniques require strong laboratory capacities,
good quality control procedures, and remain relatively
expensive. In recent years, some improvements have
been made, such as isothermal amplification steps,
the inclusion of internal amplification controls to
ensure that inhibitors (resulting in false negatives) are
not present, the design of single-tube reactions to
reduce contamination and the development of
detection by emitted light or by dipstick.
The use of NAA techniques remains technically
challenging. Despite being usually highly
specific, NAA tests have lower (and greatly variable)
sensitivity. A positive NAA test is considered good
evidence of infection but a negative result is not
informative enough. Use of NAA tests has not been
recommended for sputum negative patients. As these
3.3 Nucleic Acid Amplification (NAA)
tests cannot distinguish live from dead bacteria, they
cannot be used for patients receiving treatment. One
study considered that current NAA tests cannot replace
microscopy or culture, and should be used only in
conjunction with these tests and clinical data
31,32.
While some NAA assays reported seem to work quite
well (sometimes sensitivities near 90% were reported),
there is very wide variability, even from very resource-
rich laboratories, making their use in the field
uncertain. Their difficulty of use and quality control
issues combined with the variability and lack of
sensitivity in sputum negative and extrapulmonary TB
do not support their use
33.
The following table shows existing PCR techniques for
diagnosis of M. Tuberculosis.
Name of test
Amplified
Mycobacterium
Tuberculosis
Direct Test
AMPLICOR®
MTB tests
Company 
Gen-Probe Inc.
(USA)
Roche
Diagnostic
Systems
(USA)
Principle 
Isothermal NAA. Gen-
Probe
Amplified™ MTD Test
detects M. Tuberculosis
rRNA. The test is specific
for M.tb complex. Is an
isothermal TMA
(transcription-mediated
amplification) test in
which the target is the
mycobacterial 16SrRNA.
The entire process is
performed at 42ºC.
PCR test targeting the
16SrRNA gene.
The process can be
automatically
performed on the Roche
COBAS AMPLICOR
machine.
Advantages 
Highly specific.
Very rapid
(turnaround
time of 2.5 hours)
The first test to be
FDA approved for
smearpositive
respiratory
specimens.
Very rapid
(turnaround time 
of 6 to 7 hours)
The FDA have
approved this
method for 
testing smear
positive respiratory
specimens.
Disadvantages 
Expensive;
Requires highly
skilled personnel;
Requires dedicated
pre- and post- PCR
rooms to avoid
contamination.
As above
Interest for 
peripheral lab
settings?
Unlikely to be
usable in
peripheral
settings due
to technical
constraints of
NAA tests
As above22
Name of test
BD ProbeTec
ET® assay
In-house PCR
Real-time PCR
Company 
Becton
Dickinson
Biosciences
(USA)
N/A
N/A
Principle 
Isothermal NAA.
Isothermal SDA (strand
displacement
amplification) process in
which target sequences
of IS6110 and 16S-rRNA
gene are co-amplified.
Simultaneous
amplification and
detection is performed at
a single temperature in
the ProbeTec instrument.
“Home brew” NAA
assays. 
Most protocols use the
repeat insertion
sequence IS6110 as a
target for amplification.
This sequence is specific
to the M. Tuberculosis
complex and is present
in many copies in the 
M. Tuberculosis genome.
Real-time PCR N/A Real-
time PCR techniques
have also been
introduced for rapid
detection of rifampicin
resistance. Different
probes have been used
like the TaqMan probe,
fluorescence resonance
energy transfer (FRET)
probes, molecular
beacons and bioprobes.
Real-time PCR was
initially applied to M.
tuberculosis strains but
more recently it has been
successfully applied
directly in clinical
samples
34,35.
Advantages 
Very rapid
(turnaround
time of 3.5 to 4
hours)
Often cheaper than
commercial kits
May have less
problems with cross
contamination as
the detection takes
place in a closed
system, no need for
separate detection
room.
Disadvantages 
As above
Same limitations as
for other NAA
techniques. Lack of
standardisation may
make it difficult to
compare between
different centres or
studies. Each test
needs its own
validation studies.
Expensive
equipment and
reagents.
Requires skilled
personnel
Interest for 
peripheral lab
settings?
As above
As above
Prohibitively
expensive, but
even if it were
less expensive,
the technology
and sample
preparation
complexity make
it almost
impossible to use
in peripheral
laboratories.
A further PCR test for the diagnosis of M. Tuberculosis is under development:23
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Eiken Chemical Co Ltd (Japan).
Yes (since July 2005).
LAMP (loop mediated isothermal amplification) is a method to amplify TB DNA directly
from clinical samples. A positive result is signalled by a colour reaction visible to the
naked eye.
The format under development is an adaptation of an existing technology. The
technique requires sample preparation after the decontamination process and a
special extraction device, then isothermal amplification and detection of a
fluorescence signal, leading to a qualitative result. Apparently no cross-reaction with
M. avium.
A more direct method using sputum without decontamination of samples gives less
specific results on negative samples, and a higher incidence of false positive results.
The test is currently in development, it is being evaluated in comparison to culture.
The sensitivity claimed is ten copies of TB DNA, which is comparable to culture. This
however needs to be determined, as does the correlation with clinical stage.
A prototype is apparently being evaluated in Peru and Tanzania with good preliminary
results compared to classical PCR.
The development of a second generation test is scheduled but when MSF met with
the company, they were unclear on where the test was to be used or what the
optimal requirements would be. The estimated price would be US$ 5 per test.
(Information based on a meeting with Eiken representatives and Martine Guillerm,
MSF).
This is a simplified NAT test, suitable in theory for the monitoring of treatment.
Results are supposed to be obtained in two hours. Sample preparation apparently
has been simplified.
We have no recent information about the stage of development or whether the format
is feasible.
The feasibility of using the test at the district hospital level is of concern, and the test
may be unsuitable for use at the periphery due to the complexity of the process.
Certain specific equipment is needed. Reagents currently require cold storage. Heat
stability studies are on going. Data on cross contamination and test performance are
needed.
Greater information on non-pulmonary samples or potential use in children is needed.
If this test can be made sufficiently simple, it could be interesting, given its high
sensitivity. The procedure would require staff with PCR training however, and so its
use may be limited for the periphery. The technical platform is being investigated by
FIND for implementation in other diseases. However, many of the same technical
concerns and reservations remain.
Simplified NAT test, TB-LAMP test24
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Company
In the FIND portfolio?
Principle
Two other tests have been commercialised for drug sensitivity testing:
Innogenetics (Belgium).
No.
Two Inno-LiPa assays are commercialised. The first is for tuberculosis diagnosis
(INNO-LiPA Mycobacteria Assay), the second for detection of rifampicin resistance
(INNO-LiPA Rif TB Assay).
The LiPA assay is based on the hybridization of amplified DNA (mycobacterial 16S-
23S rRNA spacer region) from cultured strains or clinical samples to 10 probes
covering the core region of the rpoB gene of M.Tb, immobilized on a nitrocellulose
strip
36,37.
Commercialised. Transfer of technology is being explored.
It is possible to use INNO-LiPA Rif TB Assay to confirm TB infection and to detect
resistance to rifampicin at the same time.
The test is fairly robust, and easy to use in a routine PCR laboratory.
The test is extremely expensive, at Euro 40 a sample.
It also lacks an internal control, and data on its sensitivity are contradictory.
Sensitivity is lower from sputum or other patient samples.
Tests not easy to perform in the very large numbers likely be needed if routine
resistance testing is adopted.
Although the INNO-LiPA Rif TB Assay offers resistance information in 48 hours, PCR
is in general not suitable for peripheral use. The limited sensitivity from sputum
make its use limited.
Hain Lifesciences (Germany).
Yes (since October 2006).
Two GenoTypes are commercialised. The first is for tuberculosis diagnosis
(GenoType Mycobacteria Assay), the second for detection of rifampicin and isoniazid
resistance (GenoType MTBDR Assay). Isolation is commonly done by PCR
amplification of the 16S-23S ribosomal DNA spacer region followed by hybridization
of the biotinylated amplified DNA products with 16 specific oligonucleotide
probes. The specific probes are immobilized as parallel lines on a membrane strip.
GenoType Assays
INNO-LiPa assays25
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
The GenoType MTBDR detects resistance to isoniazid and rifampicin in culture
samples, based on the detection of the most common mutations in the katG and
rpoB genes respectively
38.
Commercialised.
It is possible to use Genotype MTBDR Assay to confirm TB infection and detect
resistance to rifampicin and isoniazid at the same time.
The tests are not validated yet on direct clinical samples and sensitivity is not
known. Test is only for use on smear positive samples.
Tests not easy to perform in the very large numbers likely be needed if routine
resistance testing is adopted.
Although Genotype MTBDR Assay would enable resistance testing, it comes with
the usual caveats about PCR and its unsuitability for peripheral settings. Use from
direct sputum remains to be determined. Only useful for smear positive patients,
therefore does not cover most patients (e.g. HIV co-infected). May not be able to
process large numbers of samples. 
N/A.
No.
Specific M. Tuberculosis genetic material is amplified and sequenced, allowing the
DNA to be “read”. This is the gold standard and the most widely used method for
defining genetic resistance for drug sensitivity testing. It has been commonly used
for characterizing mutations in the rpoB gene in rifampicin-resistant strains and to
detect mutations responsible for other anti-tuberculosis drugs
39,40,41. Most protocols
include the repeat insertion sequence IS6110 as a target for amplification. This
sequence is specific of M. Tuberculosis complex and is present in many copies in
the M. Tuberculosis genome.
The technique is the gold standard for monitoring resistance.
PCR sequencing gives specific strain and mutation information.
Using the technique requires sequencing capacity and sophisticated laboratory
technology.
PCR sequencing detects only some mutations, and only gives a “theoretical” result
(as opposed to culture, which gives a “functional” result).
The technique may be needed in epidemiology or surveillance programmes, but is
not suitable for use in routine patient care.
Additional nucleic acid amplification techniques include:
PCR sequencing26
Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
N/A.
No.
The basic technique consists of conducting PCR directly on samples washed off
sputum slides. Different methods have been used
42,43,44.
Early research stage.
The technique may be more sensitive than microscopy alone.
It may also be a way to ship samples to reference laboratories for testing.
The technique is not well validated.
There is a high risk of contamination, in addition to all the associated difficulties of
PCR.
Unlikely to have advantages over other techniques for peripheral laboratories, but
may be a way to ship samples for processing at a reference laboratory. 
The technique needs more validation before it can be considered.
PCR directly from AFB slides
Cellestis (Australia/USA) for Quantiferon, and Oxford Immunotec (UK) for TB Elispot.
FIND to fund evaluation study of Quantiferon.
These were touted as a replacement to Mantoux test (tuberculin skin testing). Blood is
taken from a patient, and placed in an incubator for 12 hours in sterile culture with the
tuberculin antigen. The tests measure release of a protein that is associated with
immune activation. If a patient has previously mounted an immune response to TB,
they will have cells in their blood that respond to the presence of the tuberculin
antigen. These “primed” cells then produce the immune response measured in the test.
Several versions of the tests have been released, including some as a kit with all the
required reagents. These tests are being validated in children and HIV+ patients.
24 hour result; requires blood therefore can be used on patients unable to produce
sputum, and may detect extra-pulmonary form.
3.4 Other non-culture techniques
T-cell based tests
Companies
In the FIND portfolio?
Principle
Stage of development
AdvantagesDisadvantages
Interest in peripheral
laboratory settings?
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Company
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Blood must be incubated within 12 hours of the draw. A result is known after 24 hours,
which means that the patient needs to come back to the clinic to be treated, which is
less desirable.
The tests require complex and sensitive laboratory manipulations. 
The Elisa format tests require precise pipetting, reagents require storage at 4 - 8°C and
an electricity supply.
There are also individual variations in the immune response that can make the results
difficult to interpret.
Current versions are not simple, robust diagnostic tests and many technical and medical
questions remain associated with its use.
Currently, very limited. The tests do not give a positive diagnosis in itself - a positive
result is suggestive of previous TB exposure, but is not necessarily informative about
current disease status. The tests alone are not enough for a diagnosis (or exclusion) of
TB and the interpretation of test results is not clearly defined. The relationship between
detection of latent and active disease has been questioned.
More information and investigation are needed.
Transdermal patch test for active TB
Sequella (USA).
No - the test was removed from FIND’s portfolio in 2005.
This was touted as a replacement to Mantoux test, both to allow distinction between
active and latent infection and to allow monitoring of treatment success. The test is a
transdermal patch containing a TB protein, to be applied on the forearm. It leaves a
red spot after a few hours if the patient has been exposed to TB.
An evaluation study was conducted in South Africa showed 65% sensitivity and
96% specificity.
Test delivered at point-of-care. Non-invasive technique that requires no sample
collection or handling. The company claims the test detects active TB only.
Signal is not clearly visible on dark skin.
Its use is unclear in patients in high prevalence regions.
A follow-up visit is required to read the result.
More evaluation is needed as not enough data are available yet.
The non-invasive method is a plus. More evaluation is needed, especially in HIV+
patients. The need for a follow-up visit to read the results on the patient’s arm may
limit its usefulness. The true performance of the test is not yet known.28
Companies
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Companies
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
Not commercialised, research tool.
No.
This proposed new molecular method for detecting drug resistance in M.Tb is based on
the hybridization of DNA obtained from clinical samples to oligonucleotides immobilised
on a solid support, such as miniaturized glass slides.
Microarrays have been mainly used to detect resistance to rifampicin
45.
The technique is used in some research laboratories but it is unclear whether it will
be developed further.
Some groups are looking at hand-held “chip” versions as point-of-care tools.
Rapid (~2 hrs); can be used to answer specific research questions.
Expensive; beyond reach of most clinical mycobacteriology laboratories anywhere
in the world. Technology complex and not adapted to routine use.
Not suitable for use in the periphery. The technology may however be developed into a
point-of-care format, which may be useable in some settings, although it will likely
always remain dependent on a particular machine or technology.
Various companies/researchers identified.
No.
Various methods exist to detect DNA sequences without amplification. For example, a
probe binds to the specific target, thereby uncovering the catalytic site buried in the
probe molecule. The exposed catalyst acts to change the colour of the buffer.
Still in early stages of development, although very little information available
The techniques do not need NAA and therefore may be simpler to perform and more
robust, as well as being less prone to contamination problems.
Sample will nevertheless need preparation (DNA extraction and/or purification and
concentration); sensitivity of detection may be difficult to achieve.
Depends on how the technology is developed, but a potentially simplified detection can
be imagined.
Non-NAA based DNA detection
DNA Microarrays29
Various companies/researchers identified.
One UK-based group in FIND portfolio, other groups are also active.
Detection of volatile organic compounds in the breath of TB patients relative
to controls.
Currently at the research stage. Many attempts have been made but the technology
is not very specific yet.
The Royal Tropical Institute in Amsterdam (KIT), in partnership with academic
laboratories, are developing an electronic nose
46, as are some companies.
Non-invasive technique.
Possibly no reagents or consumables.
High throughput possible.
May detect only pulmonary form; 
Technically difficult to develop a breath test that is both specific and sensitive; 
Will remain “machine dependent”.
No field prototypes are available yet. The non-invasive nature and the ability to screen
large numbers of patients would make such a test interesting, but the technology
seems to be a long way from being developed, despite some recent promising
results
47,48.
Companies
In the FIND portfolio?
Principle
Stage of development
Advantages
Disadvantages
Interest in peripheral
laboratory settings?
One final technique warrants mention. The gel
microdrop DST assay method encapsulates single cells
in an agarose matrix and measures growth in the
presence of antibiotics by flow cytometry
49.
Although in its current format this method would not
be practical for use in the peripheral laboratory
setting, its use might be developed. Further
investigations would be necessary.
Breath detection methods30
too long for a patient that has suspected XDR TB but
acceptable in a patient that is HIV negative. A test to
be used in a remote health post with no doctor will
have different requirements than a test to determine
whether it is safe to put an HIV positive person on
INH prophylaxis. A test to determine latent TB will be
of limited use if there are no facilities or structures to
deliver drugs or no agreement on whether latent TB
should be treated.
4.2 Specifications must be defined
4.2.1 One size does not fit all
No one test will fit all the gaps. Armed with precise
specifications and medical parameters, scientists and
industry can aim to address specific TB patient
populations that today are desperately neglected.
These include children, TB/HIV co-infected patients,
and patients infected with drug-resistant strains.
Specific tests and strategies are likely to be needed
for diagnosis of TB, especially in high HIV prevalence
areas, in settings with high drug resistance prevalence,
and detection of treatment failure. These
considerations should inform and direct any priority-
setting exercise to identify urgent needs.
4.3 The tests should be designed to 
be used where the patients are
Today, a significant number of tests suitable for
reference laboratories or for district hospitals are
being developed, although the majority of patients in
urgent need of diagnosis are in the most remote or
unsupported settings. 
Given the number of people at risk, methods will need
to be rapid, high throughput and inexpensive. To
simplify the already complex process of patient
management, and given the lack of human resources
in many settings, the techniques should be point of
care and rapid, so that patients are not required to
return to the clinic.
A point of care tool to reach the widest patient pool is
important, but so is how to integrate these tests into
patient management if there is limited health
infrastructure, resources and trained staff.
This overview of the research and development
pipeline for tuberculosis diagnostics and drug
sensitivity testing gives a mixed picture. On the one
hand, the pipeline is unquestionably active, with a
number of different tracks being explored, culture or
otherwise, and some improvements have been made.
However, if it is now possible to increase throughput,
or obtain results faster than can be achieved with
traditional culture methods, these improvements often
come at the expense of sensitivity and simplicity.
In part this is due to the complexity of the problem.
However, it is also revealing of a certain number of
shortcomings in the way R&D is conducted for TB
diagnostics today:
4.1 Diagnostic development must be 
based on an assessment of medical
needs
4.1.1 Diagnostic development must start with the field
specifications
The development of tests should be based on medical
needs at the field level, and aim to answer specific
questions raised by field practitioners. A critical pre-
requisite for the tuberculosis diagnostic pipeline is for
there to be consensus from the medical community on
the main gaps that are to be addressed by any newly
developed tool. Precise medical specifications must be
explored, and defined, in order to guide scientists and
the industry. Contact and collaboration between
clinical and scientific communities must be reinforced:
the medical end-users of the tests must feed into the
test development pathway.
4.1.2 Diagnostic development must include a
discussion of the medical algorithm within which the
test is to be used
It is not useful to develop a test with no prior
consideration of the medical context in which it will be
used. Developers must consider how a test will be
interpreted by practitioners, what information the test
can give and how that information will be used to
make a medical decision.
For example, knowing what mutation a patient has to
a particular antibiotic will not help the doctor choose
a treatment - it is more important to know the DST
profile. A test that gives a result in one week may be
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4.3.1 There is insufficient knowledge about local
conditions
Very few of the companies approached for this analysis
were well-briefed about the working conditions, including
human, financial and technical resources, in peripheral
settings. There is a need to distribute information about
the reality of field conditions. Technical specifications of
the new tests to be developed must be defined and
made very clear, and must form the starting point of
research and development.
4.3.2 High-tech strategies should not be force-fit to
low-tech settings
It is tempting to take existing or nearly finalised
technologies developed for highly equipped, resource-
rich settings, and implement them in developing
countries. However, we have too many examples of
how this is not an appropriate approach. For example,
focusing R&D efforts on adapting an Elisa format for
peripheral laboratories or on developing an integrated
nucleic acid amplification test ignores local needs and
conditions, and will not deliver a diagnostic tool
usable where it is most needed. A more useful
approach would be to develop an integrated strategy
that uses available tools in suitable supported
settings in the interim, with active research into
improving the options based on the approaches
discussed above.
4.3.3 Simplification is needed in the interim
As part of a short- to medium-term strategy, existing
technologies must be simplified, and alternative uses
for them devised. Some tools, such as thin layer
culture or manual MGIT, may be ready for immediate
field implementation in specific settings provided they
are introduced with a specific algorithm prepared in
collaboration with clinicians. Despite the serious
limitations of current diagnostics, their use should be
optimized. In many settings this is not done.
4.4 Fundamental research questions
must be addressed
TB diagnosis is very complex, largely because we do
not really understand the disease and much of its
fundamental biology. Some of these unanswered
fundamental questions include how M.Tb hides from
the immune system, the relationship between infection
and disease, the type of antibody response, the
bacterial load in different body sites. The underlying
knowledge base can only be strengthened through a
comprehensive strategy that prioritizes understanding
the disease. It is not enough to “wait and see”
whether existing tools can be adapted to resource-
poor settings, or to hope for the “magic bullet” before
addressing these questions. If a concerted effort is not
put into fundamental research and into missing areas
of knowledge, existing gaps will remain unchanged,
and appropriate tools will continue to lack.
4.4.1 Public leadership is required in priority setting
There is a huge resource gap in TB R&D, and in
particular in TB diagnostics, that cannot be filled only
by the private sector. Governments and public agencies
must take a leadership role in setting priorities and
providing the necessary resources in order to ensure
that appropriate tools are developed. Creation of a
new inter-governmental working group on R&D as
mandated by the World Health Assembly in 2006 could
provide the necessary framework for action. 
Scientists, doctors, public health specialists, laboratory
technicians, and FIND should share information and
resources, and work together to develop an integrated
strategy. This should include groups from areas of
expertise other than tuberculosis, who may provide
innovative solutions to long standing difficulties (for
example for ways to improve the sensitivity of rapid
diagnostic tests).
4.4.2 Independent evaluation of new tools must be
performed
There is a need for appropriate, high quality,
independent evaluation studies of tests. To avoid any
possible conflicts of interest, the bodies evaluating the
test should be separate from the test developers or
sponsors.
4.5 Access and pricing issues must
be clarified
If interesting tools are priced beyond the reach of
developing country health systems, access barriers will
not be resolved. Crucial questions remain unanswered
here. The Foundation for Innovative New Diagnostics,
for example, negotiates rights with companies to
provide the tests “at affordable prices” to the public
sector in developing countries. Who defines what is
affordable? What of pricing issues for tests developed
outside of the FIND portfolio? Will companies provide
tools at affordable levels? What about countries in
which the public sector is weak and patients are
obliged to go to the private sector for care?32
Conclusion
We repeat our call for greater transparency, public leadership in priority setting, funding for R&D for TB
diagnostics, and sharing of resources and information in a unified struggle against this terrible illness. In
addition, field needs should guide product development. While the situation is bleak in terms of a “magic bullet”
to be implemented in the field today, there is more research, funding and interest internationally than ever before
in developing appropriate diagnostic tools. In the immediate term, we can make better use of existing tools. At
the same time, we should invest resources in the development of alternatives. 
We hope that some of the recommendations proposed here will contribute to the development of improved
diagnostic tools.33
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